FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564548469> ?p ?o ?g. }

• W2564548469 endingPage "1353" @default.
• W2564548469 startingPage "1345" @default.
• W2564548469 abstract "BACKGROUND Despite controversy surrounding its benefit, the use of concomitant chemoradiotherapy (CCRT) in patients with oropharyngeal squamous cell carcinoma (OPSCC) who are aged > 70 years is increasing. However, to the authors' knowledge, few studies to date have compared the outcomes of different systemic treatments in this population. METHODS Records from 74 patients aged ≥ 70 years with stage III to stage IVB OPSCC who were undergoing CCRT from 2002 to 2013 at a single institution were reviewed. Patients were stratified according to the systemic therapy received, including cisplatin, carboplatin with either 5-fluorouracil or paclitaxel (CARB), or cetuximab to compare oncologic outcome and toxicity. RESULTS The median follow-up was 36 months. The median age of the patients was 75.3 years (range, 70-91 years), with significantly older patients receiving cetuximab (P = .03). A total of 28, 20, and 26 patients, respectively, received CCRT with cisplatin, CARB, and cetuximab. RT interruptions of > 1 day were needed in 4% of patients receiving cisplatin, 20% of patients receiving CARB, and 15% of patients receiving cetuximab (P = .19). Unplanned hospitalizations during CCRT occurred in 25%, 55%, and 58%, respectively, of patients receiving cisplatin, CARB, and cetuximab (P = .03). There were 2 treatment-related deaths, both of which occurred among the patients who were treated with cetuximab. At 5 years, locoregional control was achieved in 100%, 88%, and 60% (P<.001), respectively, and the overall survival rate was 87%, 61%, and 47% (P = .03), respectively, among patients treated with cisplatin, CARB, and cetuximab. CONCLUSIONS Toxicity from CCRT remains a challenge for older adults with OPSCC. Herein, the authors found no evidence that this toxicity was mitigated by treatment with cetuximab. Nevertheless, a subset of patients aged ≥70 years appear to tolerate cisplatin-based treatment with acceptable toxicity and excellent outcomes. Further identification of this patient subgroup is crucial to optimize therapy for older patients with OPSCC. Cancer 2017;123:1345–1353. © 2016 American Cancer Society." @default.
• W2564548469 created "2017-01-06" @default.
• W2564548469 creator A5002723616 @default.
• W2564548469 creator A5010046486 @default.
• W2564548469 creator A5012145979 @default.
• W2564548469 creator A5027048828 @default.
• W2564548469 creator A5034787589 @default.
• W2564548469 creator A5048118946 @default.
• W2564548469 creator A5048304251 @default.
• W2564548469 creator A5051075802 @default.
• W2564548469 creator A5052610122 @default.
• W2564548469 creator A5061365371 @default.
• W2564548469 creator A5063600668 @default.
• W2564548469 creator A5067395984 @default.
• W2564548469 creator A5079162702 @default.
• W2564548469 date "2016-12-16" @default.
• W2564548469 modified "2023-10-12" @default.
• W2564548469 title "The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era" @default.
• W2564548469 cites W1488865780 @default.
• W2564548469 cites W1519189106 @default.
• W2564548469 cites W1528443064 @default.
• W2564548469 cites W1554549663 @default.
• W2564548469 cites W1556413243 @default.
• W2564548469 cites W1976570736 @default.
• W2564548469 cites W1978150342 @default.
• W2564548469 cites W1982242170 @default.
• W2564548469 cites W2020727031 @default.
• W2564548469 cites W2039479761 @default.
• W2564548469 cites W2066780876 @default.
• W2564548469 cites W2069913533 @default.
• W2564548469 cites W2089257078 @default.
• W2564548469 cites W2110664940 @default.
• W2564548469 cites W2111442242 @default.
• W2564548469 cites W2114041936 @default.
• W2564548469 cites W2128590659 @default.
• W2564548469 cites W2132239791 @default.
• W2564548469 cites W2138716164 @default.
• W2564548469 cites W2140110477 @default.
• W2564548469 cites W2146955099 @default.
• W2564548469 cites W2148122005 @default.
• W2564548469 cites W2151730005 @default.
• W2564548469 cites W2153294383 @default.
• W2564548469 cites W2153759214 @default.
• W2564548469 cites W2154083484 @default.
• W2564548469 cites W2154221980 @default.
• W2564548469 cites W2155384808 @default.
• W2564548469 cites W2171524637 @default.
• W2564548469 cites W2226272315 @default.
• W2564548469 cites W2293600379 @default.
• W2564548469 cites W2468155864 @default.
• W2564548469 doi "https://doi.org/10.1002/cncr.30495" @default.
• W2564548469 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5384883" @default.
• W2564548469 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27984656" @default.
• W2564548469 hasPublicationYear "2016" @default.
• W2564548469 type Work @default.
• W2564548469 sameAs 2564548469 @default.
• W2564548469 citedByCount "18" @default.
• W2564548469 countsByYear W25645484692017 @default.
• W2564548469 countsByYear W25645484692018 @default.
• W2564548469 countsByYear W25645484692019 @default.
• W2564548469 countsByYear W25645484692020 @default.
• W2564548469 countsByYear W25645484692021 @default.
• W2564548469 countsByYear W25645484692022 @default.
• W2564548469 countsByYear W25645484692023 @default.
• W2564548469 crossrefType "journal-article" @default.
• W2564548469 hasAuthorship W2564548469A5002723616 @default.
• W2564548469 hasAuthorship W2564548469A5010046486 @default.
• W2564548469 hasAuthorship W2564548469A5012145979 @default.
• W2564548469 hasAuthorship W2564548469A5027048828 @default.
• W2564548469 hasAuthorship W2564548469A5034787589 @default.
• W2564548469 hasAuthorship W2564548469A5048118946 @default.
• W2564548469 hasAuthorship W2564548469A5048304251 @default.
• W2564548469 hasAuthorship W2564548469A5051075802 @default.
• W2564548469 hasAuthorship W2564548469A5052610122 @default.
• W2564548469 hasAuthorship W2564548469A5061365371 @default.
• W2564548469 hasAuthorship W2564548469A5063600668 @default.
• W2564548469 hasAuthorship W2564548469A5067395984 @default.
• W2564548469 hasAuthorship W2564548469A5079162702 @default.
• W2564548469 hasBestOaLocation W25645484691 @default.
• W2564548469 hasConcept C121608353 @default.
• W2564548469 hasConcept C126322002 @default.
• W2564548469 hasConcept C141071460 @default.
• W2564548469 hasConcept C143998085 @default.
• W2564548469 hasConcept C2776694085 @default.
• W2564548469 hasConcept C2778239845 @default.
• W2564548469 hasConcept C2778424827 @default.
• W2564548469 hasConcept C2779384505 @default.
• W2564548469 hasConcept C2779998722 @default.
• W2564548469 hasConcept C2781451048 @default.
• W2564548469 hasConcept C2908647359 @default.
• W2564548469 hasConcept C509974204 @default.
• W2564548469 hasConcept C526805850 @default.
• W2564548469 hasConcept C71924100 @default.
• W2564548469 hasConcept C99454951 @default.
• W2564548469 hasConceptScore W2564548469C121608353 @default.
• W2564548469 hasConceptScore W2564548469C126322002 @default.
• W2564548469 hasConceptScore W2564548469C141071460 @default.
• W2564548469 hasConceptScore W2564548469C143998085 @default.

• next